Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Vitreomacular Interface Abnormalities in Multiple Sclerosis; A Novel Signature of Disability
Multiple Sclerosis
P10 - Poster Session 10 (8:00 AM-9:00 AM)
3-013
Optical coherence tomography (OCT) allows high-resolution visualization of the retina, including vitreomacular interface abnormalities (VMIAs), such as epiretinal membranes. Correlations between blood-retinal barrier (BRB) dysfunction and VMIAs exist. Since BRB disruption may occur in multiple sclerosis (MS), elucidating VMIAs’ clinical relevance in people with MS (PwMS) is of interest, and remains largely unexplored.
To investigate the clinical (expanded disability status scale [EDSS] and visual function [VF]) measures, and retinal layer thickness differences between PwMS with (VMIA+) and without VMIAs (VMIA-).
In this cross-sectional study, 1463 PwMS (2926 eyes) underwent Cirrus HD-OCT imaging, with automated macular layer segmentation. VMIA presence was recorded. The VMIA+ and VMIA- groups were age and sex matched. EDSS, VF, and retinal layer thicknesses were analyzed using linear regression. Odds ratios (ORs) were estimated using logistic regression. 

VMIAs were found in 95 PwMS (prevalence = 6.5%). The mean age and sex distribution of the VMIA+ (60.2 years, 72% female) and VMIA- (57.5 years, 79% female) cohorts were comparable. VMIA presence was associated with higher EDSS (difference 0.7, CI: 0.1-1.4, p=0.03), with the odds of having an EDSS>4 2.2 times higher in VMIA+, as compared to VMIA- (CI=1.21-4.16, p=0.01) PwMS. Inner nuclear layer (INL), outer nuclear layer (ONL), and retinal pigment epithelium (RPE) thicknesses were -0.98 µm (p=0.05), -2.84 µm(p=0.002) and -0.76 µm(p=0.001) respectively lower in the VMIA+ cohort. VF outcomes were similar between the groups.

Our findings suggest VMIAs may identify an MS phenotype associated with greater disability, that is unrelated to visual dysfunction. Retinal inflammation disrupting BRB may activate Müller glia, potentially explaining why VMIA presence in PwMS correlate with greater disability. Müller glia in the INL and RPE cells may potentially migrate, possibly explaining INL and RPE thickness reductions in PwMS with VMIAs. Furthermore, disrupting the highly susceptible photoreceptors by VMIAs might reduce ONL thickness.
Authors/Disclosures
Hussein Moussa, MD (Indiana University SOM)
PRESENTER
Dr. Moussa has nothing to disclose.
Grigorios Kalaitzidis, MD (Boston University Medical Center) Mr. Kalaitzidis has nothing to disclose.
Henrik Ehrhardt, MBBCh (Rutgers - Robert Wood Johnson Medical School) Henrik Ehrhardt has nothing to disclose.
Olwen Murphy, MD (Johns Hopkins Hospital) Dr. Murphy has nothing to disclose.
Eleni Vasileiou, MD (Mount Sinai) Dr. Vasileiou has nothing to disclose.
Gelareh Ahmadi, MD,FRACP,PhD Dr. Ahmadi has nothing to disclose.
Kathryn Fitzgerald, PhD (Johns Hopkins University) The institution of Dr. Fitzgerald has received research support from NIH. The institution of Dr. Fitzgerald has received research support from National MS Society.
Sahi Nandini Wuppukondur, Other Ms. Wuppukondur has nothing to disclose.
Sujata Rijal, PhD Dr. Rijal has nothing to disclose.
Scott Douglas Newsome, DO, FAAN (Johns Hopkins Hospital) Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Greenwich Biosciences. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. The institution of Dr. Newsome has received research support from Biogen. The institution of Dr. Newsome has received research support from Genentech/Roche. The institution of Dr. Newsome has received research support from Department of Defense. The institution of Dr. Newsome has received research support from Patient Centered Outcomes Research Institute. The institution of Dr. Newsome has received research support from National MS Society. The institution of Dr. Newsome has received research support from The Stiff Person Syndrome Research Foundation. The institution of Dr. Newsome has received research support from Lundbeck. Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving as a Lead PI for Clinical Trial with Roche.
Elias S. Sotirchos, MD (Johns Hopkins University) Dr. Sotirchos has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ad Scientiam. Dr. Sotirchos has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viela Bio. Dr. Sotirchos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Sotirchos has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Sotirchos has received research support from National Institutes of Health. The institution of Dr. Sotirchos has received research support from National Multiple Sclerosis Society. The institution of Dr. Sotirchos has received research support from Sumaira Foundation. The institution of Dr. Sotirchos has received research support from Genentech. Dr. Sotirchos has received personal compensation in the range of $500-$4,999 for serving as a Ad Hoc Reviewer with National Institutes of Health.
Peter A. Calabresi, MD, FAAN (Johns Hopkins University) Dr. Calabresi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Calabresi has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Idorsia. An immediate family member of Dr. Calabresi has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MyMD. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Myelin Repair Foundation. The institution of Dr. Calabresi has received research support from Genentech. Dr. Calabresi has received publishing royalties from a publication relating to health care. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Study Section Member with NIH. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Grant reveiwer with Myelin Repair Foundation. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Speaker for CME with NYAS. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Academic CME.
Amir H. Kashani, MD,PhD Dr. Kashani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Carl Zeiss Meditec. The institution of Dr. Kashani has received research support from Carl Zeiss Meditec.
Shiv Saidha, MD (Johns Hopkins) Dr. Saidha has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ReWind Therapeutics. Dr. Saidha has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Saidha has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Saidha has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Clene Pharmaceuticals. Dr. Saidha has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Saidha has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Saidha has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Saidha has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Multiple Sclerosis Journal ETC. Dr. Saidha has stock in June Brain. Dr. Saidha has stock in Lapix Therapeutics. The institution of Dr. Saidha has received research support from Biogen. The institution of Dr. Saidha has received research support from Genentech. The institution of Dr. Saidha has received research support from Novartis. The institution of Dr. Saidha has received research support from Lapix Therapeutics. The institution of Dr. Saidha has received research support from Novartis.